CD274 and neoplasm: vs. 14.2 mo.; HR, 0.63; 95% CI, 0.47 to 0.86; p-value = 0.002) against platinum-based chemotherapy in Keynote-042 and become available and reimbursed by the national health system (NHS) in June 2017 for patients with NSCLC with a tumor proportional score (TPS) of PDL-1 ≥ 50% [9,10].